Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-890 tablets in moderate-to-severe plaque psoriasis (Phase II, randomized, double-blind, placebo-controlled)
CTR20244757Phase 2Active
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WD-890 in plaque psoriasis, sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
WD-890
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20244757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244757.